Ionis Pharmaceuticals (IONS) Competitors

$75.12 -0.59 (-0.77%)

As of 02:18 PM Eastern

IONS vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to Ionis Pharmaceuticals' net margin of -30.91%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Alnylam Pharmaceuticals presently has a consensus price target of $471.96, suggesting a potential upside of 64.67%. Ionis Pharmaceuticals has a consensus price target of $99.35, suggesting a potential upside of 32.25%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.29B	8.93	$313.75M	$3.66	78.31
Ionis Pharmaceuticals	$944M	13.15	-$381.39M	-$2.07	N/A

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 13 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.66 beat Alnylam Pharmaceuticals' score of 0.29 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Summary

Alnylam Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Biogen?

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Biogen has a net margin of 13.81% compared to Ionis Pharmaceuticals' net margin of -30.91%. Biogen's return on equity of 12.83% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Biogen	13.81%	12.83%	8.01%

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	13.15	-$381.39M	-$2.07	N/A
Biogen	$9.94B	2.94	$1.29B	$9.32	21.27

Ionis Pharmaceuticals currently has a consensus price target of $99.35, suggesting a potential upside of 32.25%. Biogen has a consensus price target of $214.23, suggesting a potential upside of 8.09%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Biogen had 27 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 40 mentions for Biogen and 13 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.92 beat Ionis Pharmaceuticals' score of 0.66 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	12 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

United Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

United Therapeutics presently has a consensus price target of $619.42, suggesting a potential upside of 8.41%. Ionis Pharmaceuticals has a consensus price target of $99.35, suggesting a potential upside of 32.25%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, United Therapeutics had 23 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 36 mentions for United Therapeutics and 13 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.66 beat United Therapeutics' score of 0.49 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	16 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.17B	7.65	$1.33B	$27.09	21.09
Ionis Pharmaceuticals	$944M	13.15	-$381.39M	-$2.07	N/A

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 10.3% of United Therapeutics shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

United Therapeutics has a net margin of 40.62% compared to Ionis Pharmaceuticals' net margin of -30.91%. United Therapeutics' return on equity of 19.24% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Summary

United Therapeutics beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Incyte?

Ionis Pharmaceuticals (NASDAQ:IONS) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Ionis Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Incyte has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	13.15	-$381.39M	-$2.07	N/A
Incyte	$5.36B	3.74	$1.29B	$7.08	14.16

Ionis Pharmaceuticals currently has a consensus price target of $99.35, suggesting a potential upside of 32.25%. Incyte has a consensus price target of $104.26, suggesting a potential upside of 3.97%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Incyte has a net margin of 26.71% compared to Ionis Pharmaceuticals' net margin of -30.91%. Incyte's return on equity of 26.66% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Incyte	26.71%	26.66%	19.77%

In the previous week, Incyte had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 15 mentions for Incyte and 13 mentions for Ionis Pharmaceuticals. Incyte's average media sentiment score of 0.69 beat Ionis Pharmaceuticals' score of 0.66 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Incyte beats Ionis Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Ionis Pharmaceuticals (NASDAQ:IONS) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neurocrine Biosciences has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	13.15	-$381.39M	-$2.07	N/A
Neurocrine Biosciences	$2.86B	5.31	$478.60M	$6.49	23.26

Neurocrine Biosciences has a net margin of 21.55% compared to Ionis Pharmaceuticals' net margin of -30.91%. Neurocrine Biosciences' return on equity of 19.79% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Ionis Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

In the previous week, Neurocrine Biosciences had 29 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 42 mentions for Neurocrine Biosciences and 13 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.66 beat Neurocrine Biosciences' score of 0.63 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	12 Very Positive mention(s)	3 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals currently has a consensus target price of $99.35, indicating a potential upside of 32.25%. Neurocrine Biosciences has a consensus target price of $184.15, indicating a potential upside of 22.01%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Ionis Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Neurocrine Biosciences beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.44B	$3.04B	$6.20B	$12.30B
Dividend Yield	N/A	1.93%	2.78%	5.22%
P/E Ratio	-36.36	17.65	20.71	25.86
Price / Sales	13.15	278.61	549.99	74.51
Price / Cash	N/A	55.41	27.81	36.27
Price / Book	24.88	4.16	9.82	6.79
Net Income	-$381.39M	$72.19M	$3.55B	$333.31M
7 Day Performance	N/A	N/A	N/A	0.56%
1 Month Performance	-0.06%	3.56%	6.77%	9.42%
1 Year Performance	132.87%	47.57%	42.65%	43.23%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	3.7537 of 5 stars	$75.12 -0.8%	$99.35 +32.2%	+134.7%	$12.44B	$944M	N/A	1,402
ALNY Alnylam Pharmaceuticals	4.1739 of 5 stars	$297.92 +0.6%	$471.96 +58.4%	+17.1%	$39.51B	$3.71B	81.40	2,770	Analyst Revision
BIIB Biogen	3.6394 of 5 stars	$187.21 +0.1%	$214.23 +14.4%	+63.7%	$27.62B	$9.89B	20.09	7,500	Analyst Revision
UTHR United Therapeutics	3.1853 of 5 stars	$581.22 +1.9%	$601.50 +3.5%	+87.4%	$25.00B	$3.18B	20.83	1,400	Earnings Report Insider Trade
INCY Incyte	3.9596 of 5 stars	$97.14 +0.2%	$104.26 +7.3%	+67.1%	$19.36B	$5.14B	13.72	2,844

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Ionis Pharmaceuticals compare to Biogen?

Summary

How does Ionis Pharmaceuticals compare to United Therapeutics?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Summary

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Is ALNY or IONS more profitable?

Do analysts rate ALNY or IONS?

Do insiders & institutionals have more ownership in ALNY or IONS?

Which has stronger valuation & earnings, ALNY or IONS?

Does the media prefer ALNY or IONS?

Which has more risk & volatility, ALNY or IONS?

Summary

How does Ionis Pharmaceuticals compare to Biogen?

Do institutionals & insiders hold more shares of IONS or BIIB?

Which has more risk & volatility, IONS or BIIB?

Is IONS or BIIB more profitable?

Which has preferable valuation & earnings, IONS or BIIB?

Do analysts prefer IONS or BIIB?

Does the media favor IONS or BIIB?

Summary

How does Ionis Pharmaceuticals compare to United Therapeutics?

Which has more volatility and risk, UTHR or IONS?

Do analysts recommend UTHR or IONS?

Does the media prefer UTHR or IONS?

Which has better earnings & valuation, UTHR or IONS?

Do institutionals and insiders hold more shares of UTHR or IONS?

Is UTHR or IONS more profitable?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Which has more risk and volatility, IONS or INCY?

Do institutionals & insiders hold more shares of IONS or INCY?

Which has preferable valuation & earnings, IONS or INCY?

Do analysts rate IONS or INCY?

Is IONS or INCY more profitable?

Does the media prefer IONS or INCY?

Summary

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Do institutionals and insiders believe in IONS or NBIX?

Which has preferable valuation & earnings, IONS or NBIX?

Is IONS or NBIX more profitable?

Which has more risk & volatility, IONS or NBIX?

Does the media prefer IONS or NBIX?

Do analysts recommend IONS or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools